Disappointing results in Biogen MS drug trial
It had been hoped that Biogen’s experimental drug opicinumab would be able to repair mylin. As those of us who live with Multiple Sclerosis know all too well, mylin is sort of an insulator to our nerves. MS destroys mylin and, in doing so, short circuits our nervous system. Biogen announced today that Phase 2 of its opicinumab trial, named SYNERGY, failed to meet its primary goal of improving physical…Continue Reading